Bio Green Med Solution, INC. (BGMSP) — 8-K Filings

All 8-K filings from Bio Green Med Solution, INC.. Browse 50 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (50)

Bio Green Med Solution Files 8-K: Material Agreement, Equity Sales — Nov 6, 2025 Risk: medium
Bio Green Med Solution, Inc. (formerly Cyclacel Pharmaceuticals, Inc. and XCYTE THERAPIES INC) filed an 8-K on November 5, 2025. The filing indicates the compan
Bio Green Med Solution, Inc. Files 8-K on Asset Deal — Oct 7, 2025 Risk: medium
Bio Green Med Solution, Inc. (formerly Cyclacel Pharmaceuticals, Inc. and Xcyte Therapies Inc.) filed an 8-K on October 7, 2025, reporting on the entry into a m
Bio Green Med Solution, Inc. Files 8-K on Officer/Director Changes — Sep 25, 2025 Risk: medium
Bio Green Med Solution, Inc. filed an 8-K on September 25, 2025, reporting events as of September 19, 2025. The filing pertains to the departure of directors or
Bio Green Med Solution Faces Delisting Notice — Sep 16, 2025 Risk: high
Bio Green Med Solution, Inc. filed an 8-K on September 16, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company, fo
Cyclacel Pharmaceuticals Files 8-K on Asset Deal & Charter Changes — Sep 12, 2025 Risk: medium
On September 12, 2025, Cyclacel Pharmaceuticals, Inc. filed an 8-K report indicating a completion of an acquisition or disposition of assets. The filing also no
Cyclacel Pharmaceuticals Files 8-K on Shareholder Votes & Financials — Sep 5, 2025 Risk: low
Cyclacel Pharmaceuticals, Inc. filed an 8-K on September 5, 2025, reporting on matters submitted to a vote of security holders and financial statements. The fil
Cyclacel Pharmaceuticals Files 8-K: Material Agreement & Equity Sales — Sep 4, 2025 Risk: medium
On September 4, 2025, Cyclacel Pharmaceuticals, Inc. filed an 8-K report detailing a material definitive agreement. The filing also covers unregistered sales of
Cyclacel Pharmaceuticals Reports Material Definitive Agreement — Sep 2, 2025 Risk: medium
Cyclacel Pharmaceuticals, Inc. filed an 8-K on September 2, 2025, reporting a material definitive agreement. The filing does not contain specific details about
Cyclacel Pharmaceuticals Changes Certifying Accountant — Aug 28, 2025 Risk: low
Cyclacel Pharmaceuticals, Inc. filed an 8-K on August 28, 2025, reporting a change in its certifying accountant as of August 22, 2025. The filing also includes
Cyclacel Pharmaceuticals Files 8-K — Aug 13, 2025 Risk: low
Cyclacel Pharmaceuticals, Inc. filed an 8-K on August 13, 2025, reporting financial statements and exhibits as of August 12, 2025. The company, formerly known a
Cyclacel Pharmaceuticals Files 8-K — Jul 28, 2025 Risk: low
Cyclacel Pharmaceuticals, Inc. filed an 8-K on July 28, 2025, reporting amendments to its articles of incorporation or bylaws and financial statements. The comp
Cyclacel Pharmaceuticals Files 8-K — Jul 16, 2025 Risk: low
On July 15, 2025, Cyclacel Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibi
Cyclacel Pharmaceuticals Files 8-K Report — Jul 7, 2025 Risk: low
On July 7, 2025, Cyclacel Pharmaceuticals, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes Regulation FD disclosure
Cyclacel Pharmaceuticals Files 8-K with Corporate Updates — Jul 2, 2025 Risk: low
Cyclacel Pharmaceuticals, Inc. filed an 8-K on July 2, 2025, reporting amendments to its Articles of Incorporation or Bylaws, a Regulation FD disclosure, and fi
Cyclacel Pharmaceuticals Files 8-K on June 30, 2025 — Jun 30, 2025 Risk: low
Cyclacel Pharmaceuticals, Inc. filed an 8-K on June 30, 2025, reporting on matters submitted to a vote of security holders and including financial statements an
Cyclacel Pharmaceuticals Files 8-K with Key Corporate Updates — Jun 20, 2025 Risk: medium
On June 20, 2025, Cyclacel Pharmaceuticals, Inc. filed an 8-K report detailing several significant events. These include entering into a material definitive agr
Cyclacel Pharmaceuticals Changes Address — Jun 3, 2025 Risk: low
On June 3, 2025, Cyclacel Pharmaceuticals, Inc. filed an 8-K report. The filing indicates the company's address is now Level 10, Tower 11, Avenue 5, The Horizon
Cyclacel Pharmaceuticals Files 8-K on Financials — May 15, 2025 Risk: low
Cyclacel Pharmaceuticals, Inc. filed an 8-K on May 15, 2025, reporting on its results of operations and financial condition as of May 14, 2025. The filing detai
Cyclacel Pharmaceuticals Files 8-K with Bylaw Amendments — May 7, 2025 Risk: low
Cyclacel Pharmaceuticals, Inc. filed an 8-K on May 7, 2025, reporting amendments to its articles of incorporation or bylaws, a Regulation FD disclosure, and fin
Cyclacel Pharmaceuticals Files 8-K Report — May 6, 2025 Risk: low
On May 6, 2025, Cyclacel Pharmaceuticals, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes Regulation FD disclosures
Cyclacel Pharmaceuticals Files 8-K — Apr 25, 2025 Risk: low
Cyclacel Pharmaceuticals, Inc. filed an 8-K on April 25, 2025, reporting amendments to its articles of incorporation or bylaws and financial statements. The com
Cyclacel Pharmaceuticals Changes Principal Executive Offices — Apr 21, 2025 Risk: medium
On April 21, 2025, Cyclacel Pharmaceuticals, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to Kuala Lumpu
Cyclacel Pharmaceuticals Files 8-K: Operations, Officers, Financials — Apr 2, 2025 Risk: medium
Cyclacel Pharmaceuticals, Inc. filed an 8-K on April 2, 2025, reporting events as of March 31, 2025. The filing covers results of operations, financial conditio
Cyclacel Pharmaceuticals Files 8-K with Key Corporate Updates — Mar 24, 2025 Risk: medium
On March 21, 2025, Cyclacel Pharmaceuticals, Inc. filed an 8-K report detailing several significant events. These include entering into a material definitive ag
Cyclacel Pharmaceuticals Files 8-K on Key Agreements and Acquisitions — Mar 14, 2025 Risk: medium
On March 10, 2025, Cyclacel Pharmaceuticals, Inc. filed an 8-K report detailing a material definitive agreement and the completion of an acquisition or disposit
Cyclacel Pharmaceuticals Files 8-K: Delisting Notice, Control Change — Feb 27, 2025 Risk: high
Cyclacel Pharmaceuticals, Inc. filed an 8-K on February 27, 2025, reporting several material events. These include entering into a material definitive agreement
Cyclacel Pharmaceuticals Files 8-K: Material Agreement & Exhibits — Feb 24, 2025 Risk: medium
On February 20, 2025, Cyclacel Pharmaceuticals, Inc. entered into a material definitive agreement. The company also filed financial statements and exhibits as p
Cyclacel Pharmaceuticals Files 8-K on Security Holder Rights — Feb 12, 2025 Risk: medium
On February 6, 2025, Cyclacel Pharmaceuticals, Inc. filed an 8-K report detailing material modifications to security holder rights and amendments to its article
Cyclacel Pharmaceuticals Files 8-K with Key Corporate Updates — Feb 6, 2025 Risk: medium
On February 4, 2025, Cyclacel Pharmaceuticals, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity secu
Cyclacel Pharmaceuticals Files 8-K: Other Event — Feb 5, 2025 Risk: medium
On January 31, 2025, Cyclacel Pharmaceuticals, Inc. reported an "Other Event" in its Form 8-K filing. The filing does not contain specific details about the nat
Cyclacel Pharmaceuticals Files 8-K Report — Jan 10, 2025 Risk: low
On January 9, 2025, Cyclacel Pharmaceuticals, Inc. filed an 8-K report detailing a material definitive agreement and financial statements. The company, incorpor
Cyclacel Pharmaceuticals 8-K: Agreements, Equity Sales, Officer Changes — Jan 6, 2025 Risk: medium
Cyclacel Pharmaceuticals, Inc. filed an 8-K on January 6, 2025, reporting on several key events. These include entering into a material definitive agreement, un
Cyclacel Pharmaceuticals Faces Delisting Concerns — Dec 12, 2024 Risk: high
Cyclacel Pharmaceuticals, Inc. has filed an 8-K report on December 12, 2024, indicating a notice of delisting or failure to meet continued listing standards. Th
Cyclacel Pharmaceuticals Files 8-K: Agreements & Equity Update — Nov 15, 2024 Risk: medium
On November 13, 2024, Cyclacel Pharmaceuticals, Inc. entered into a Material Definitive Agreement. The company also reported on Unregistered Sales of Equity Sec
Cyclacel Pharmaceuticals to be Acquired by Verastem, Inc. — Nov 12, 2024 Risk: medium
Cyclacel Pharmaceuticals, Inc. announced on November 5, 2024, that it has entered into a definitive agreement to be acquired by Verastem, Inc. The transaction i
Cyclacel Pharmaceuticals Faces Nasdaq Delisting — Oct 24, 2024 Risk: high
Cyclacel Pharmaceuticals, Inc. filed an 8-K on October 24, 2024, reporting a notice of delisting or failure to meet continued listing standards. The company's c
Verastem to Acquire Cyclacel Pharmaceuticals — Sep 6, 2024 Risk: medium
Cyclacel Pharmaceuticals, Inc. announced on September 4, 2024, that it has entered into a definitive agreement to be acquired by Verastem, Inc. The transaction
Cyclacel Pharmaceuticals Faces Nasdaq Delisting Warning — Aug 30, 2024 Risk: high
Cyclacel Pharmaceuticals, Inc. received a notice on August 29, 2024, indicating it failed to meet the continued listing rule standards for The Nasdaq Stock Mark
Cyclacel Pharmaceuticals Faces Nasdaq Delisting Warning — Aug 26, 2024 Risk: high
Cyclacel Pharmaceuticals, Inc. announced on August 22, 2024, that it received a notification from The Nasdaq Stock Market LLC regarding its failure to meet the
Verastem to Acquire Cyclacel Pharmaceuticals for $115M — Aug 22, 2024 Risk: medium
Cyclacel Pharmaceuticals, Inc. announced on August 19, 2024, that it has entered into a definitive agreement to be acquired by Verastem, Inc. The transaction is
Cyclacel Pharmaceuticals Files 8-K on Financials — Aug 14, 2024 Risk: low
Cyclacel Pharmaceuticals, Inc. filed an 8-K on August 14, 2024, reporting on its results of operations and financial condition. The filing includes financial st
Cyclacel Pharmaceuticals Holds Annual Meeting, Elects Directors — Jun 25, 2024 Risk: low
Cyclacel Pharmaceuticals, Inc. announced on June 21, 2024, that it held its Annual Meeting of Stockholders. During the meeting, stockholders elected two Class I
Cyclacel Pharmaceuticals Files 8-K on Financials — May 14, 2024 Risk: low
On May 14, 2024, Cyclacel Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition,
Cyclacel Pharmaceuticals Files 8-K: Material Agreement & Equity Sales — May 2, 2024 Risk: medium
On April 30, 2024, Cyclacel Pharmaceuticals, Inc. entered into a Material Definitive Agreement. The company also reported on Unregistered Sales of Equity Securi
Cyclacel Pharmaceuticals Files 8-K Report — Apr 26, 2024 Risk: low
On April 26, 2024, Cyclacel Pharmaceuticals, Inc. filed an 8-K report. The filing primarily contains information related to the company's corporate structure an
Cyclacel Pharmaceuticals to Delist from Nasdaq — Mar 28, 2024 Risk: high
Cyclacel Pharmaceuticals, Inc. filed an 8-K on March 27, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company is tr
Cyclacel Pharmaceuticals Files 8-K Report — Mar 19, 2024 Risk: low
On March 19, 2024, Cyclacel Pharmaceuticals, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 200 Connell
Cyclacel Pharma 8-K: Officer/Director Changes, Potential New Communications — Jan 30, 2024
Cyclacel Pharmaceuticals, Inc. filed an 8-K on January 30, 2024, reporting an event on January 25, 2024, related to the departure or election of directors/offic
Cyclacel Confirms Nasdaq Listing for Common & Preferred Stock — Jan 12, 2024
Cyclacel Pharmaceuticals, Inc. filed an 8-K on January 12, 2024, to report that its Common Stock, with a par value of $0.001 per share, is registered on The Nas
Cyclacel Pharma 8-K: Common Stock Registered Under Exchange Act — Jan 9, 2024
Cyclacel Pharmaceuticals, Inc. filed an 8-K on January 8, 2024, primarily to disclose that its Common Stock, with a par value of $0.001 per share, is registered

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX